The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (±)-indobufen

C. Cerletti, S. Manarini, M. Colombo, A. Tavani

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The racemic compound indobufen and its (+) and (-)-enantiomers have been compared for their effects on blood platelet function and rat carrageenan pleurisy. The antiplatelet properties were sudied in-vitro in human platelets by measuring the inhibition of platelet aggregation and generation of serum thromboxane (Tx) B2. In-vivo, the antiplatelet and anti-inflammatory properties were studied in rats by measuring the inhibition of serum TxB2, the amount of 6-keto PGF(1α) in pleural exudate and pleural exudate volume. In all tests the (+)-enantiomer was slightly more potent than the racemate, while the (-)-enantiomer was far less potent. In the same rats, treatment with the lowest doses of the compounds giving 90% inhibition of serum thromboxane B2 generation was associated with occasional macroscopic lesions of the gastric mucosa.

Original languageEnglish
Pages (from-to)885-887
Number of pages3
JournalJournal of Pharmacy and Pharmacology
Volume42
Issue number12
Publication statusPublished - 1990

Fingerprint

Thromboxane B2
Anti-Inflammatory Agents
Exudates and Transudates
Blood Platelets
Serum
Pleurisy
Carrageenan
Prostaglandins F
Gastric Mucosa
Platelet Aggregation
indobufen
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (±)-indobufen. / Cerletti, C.; Manarini, S.; Colombo, M.; Tavani, A.

In: Journal of Pharmacy and Pharmacology, Vol. 42, No. 12, 1990, p. 885-887.

Research output: Contribution to journalArticle

@article{5d7171cae8154190a4246e8ba55492a4,
title = "The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (±)-indobufen",
abstract = "The racemic compound indobufen and its (+) and (-)-enantiomers have been compared for their effects on blood platelet function and rat carrageenan pleurisy. The antiplatelet properties were sudied in-vitro in human platelets by measuring the inhibition of platelet aggregation and generation of serum thromboxane (Tx) B2. In-vivo, the antiplatelet and anti-inflammatory properties were studied in rats by measuring the inhibition of serum TxB2, the amount of 6-keto PGF(1α) in pleural exudate and pleural exudate volume. In all tests the (+)-enantiomer was slightly more potent than the racemate, while the (-)-enantiomer was far less potent. In the same rats, treatment with the lowest doses of the compounds giving 90{\%} inhibition of serum thromboxane B2 generation was associated with occasional macroscopic lesions of the gastric mucosa.",
author = "C. Cerletti and S. Manarini and M. Colombo and A. Tavani",
year = "1990",
language = "English",
volume = "42",
pages = "885--887",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "12",

}

TY - JOUR

T1 - The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (±)-indobufen

AU - Cerletti, C.

AU - Manarini, S.

AU - Colombo, M.

AU - Tavani, A.

PY - 1990

Y1 - 1990

N2 - The racemic compound indobufen and its (+) and (-)-enantiomers have been compared for their effects on blood platelet function and rat carrageenan pleurisy. The antiplatelet properties were sudied in-vitro in human platelets by measuring the inhibition of platelet aggregation and generation of serum thromboxane (Tx) B2. In-vivo, the antiplatelet and anti-inflammatory properties were studied in rats by measuring the inhibition of serum TxB2, the amount of 6-keto PGF(1α) in pleural exudate and pleural exudate volume. In all tests the (+)-enantiomer was slightly more potent than the racemate, while the (-)-enantiomer was far less potent. In the same rats, treatment with the lowest doses of the compounds giving 90% inhibition of serum thromboxane B2 generation was associated with occasional macroscopic lesions of the gastric mucosa.

AB - The racemic compound indobufen and its (+) and (-)-enantiomers have been compared for their effects on blood platelet function and rat carrageenan pleurisy. The antiplatelet properties were sudied in-vitro in human platelets by measuring the inhibition of platelet aggregation and generation of serum thromboxane (Tx) B2. In-vivo, the antiplatelet and anti-inflammatory properties were studied in rats by measuring the inhibition of serum TxB2, the amount of 6-keto PGF(1α) in pleural exudate and pleural exudate volume. In all tests the (+)-enantiomer was slightly more potent than the racemate, while the (-)-enantiomer was far less potent. In the same rats, treatment with the lowest doses of the compounds giving 90% inhibition of serum thromboxane B2 generation was associated with occasional macroscopic lesions of the gastric mucosa.

UR - http://www.scopus.com/inward/record.url?scp=0025648065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025648065&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 885

EP - 887

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 12

ER -